For Quick Alerts
ALLOW NOTIFICATIONS  
For Daily Alerts

Glenmark Gets USFDA Nod For Oral Contraceptive Drug; Shares Up

|

Glenmark Pharmaceuticals today said it has received final approval from the US health regulator to sell oral contraceptive -- drospirenone and ethinyl estradiol tablets -- in the US market.

The shares were up a huge 4 per cent following the reports of the approval and were last trading at Rs 1209.

Glenmark Gets USFDA Nod For Oral Contraceptive Drug; Shares Up
Glenmark Pharmaceuticals: Quotes, News
BSE 358.40BSE Quote4.3 (-1.20%)
NSE 358.35NSE Quote4.5 (-1.26%)
"Glenmark Pharmaceuticals Inc., USA has been granted final approval by the United States Food & Drug Administration (USFDA) for Drospirenone and Ethinyl Estradiol tablets USP, 3 mg/0.02 mg," the company said in a BSE filing.
 

The product is generic version Bayer's Yaz tablets. Glenmark said it plans to commence shipping of drospirenone and ethinyl Estradiol tablets immediately. Citing IMS Health sales data, the company said for the 12 months period ending June, "the Yaz market achieved annual sales of approximately USD 170.1 million". Glenmark's shares were trading at Rs 1,213.65 apiece, up 4.62 per cent from their previous close on BSE.

With inputs from PTI

Read more about: glenmark us fda
Story first published: Wednesday, August 19, 2015, 12:14 [IST]
Company Search
Get Instant News Updates
Enable
x
Notification Settings X
Time Settings
Done
Clear Notification X
Do you want to clear all the notifications from your inbox?
Settings X
We use cookies to ensure that we give you the best experience on our website. This includes cookies from third party social media websites and ad networks. Such third party cookies may track your use on Goodreturns sites for better rendering. Our partners use cookies to ensure we show you advertising that is relevant to you. If you continue without changing your settings, we'll assume that you are happy to receive all cookies on Goodreturns website. However, you can change your cookie settings at any time. Learn more